Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Preferred Stock Liabilities (2019 - 2020)

Pliant Therapeutics (PLRX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $100.0 million as the latest value for Q1 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $100.0 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $100.0 million through Mar 2020, changed N/A year-over-year, with the annual reading at $47.9 million for FY2019, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q1 2020 was $100.0 million at Pliant Therapeutics, up from $47.9 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $100.0 million in Q1 2020, with the low at $47.9 million in Q4 2019.